← Back to patent-cliff list
CAS 461432-23-5
4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
Codes: DAPA-004, ERTU-010
Application context (from source-drug indications)
Type 2 diabetesDapagliflozin Propanediol/Metformin HydrochlorideType 2 diabetesErtugliflozinMitral regurgitationErtugliflozinLeft ventricular dysfunctionErtugliflozinHeart failureErtugliflozinAtherosclerosisErtugliflozinInsulin resistanceErtugliflozinChronic renal impairmentDapagliflozin Propanediol MonohydrateHeart failureDapagliflozin Propanediol MonohydrateKidney diseaseDapagliflozin Propanediol MonohydrateType 1 diabetesDapagliflozin Propanediol MonohydrateType 2 diabetesDapagliflozin Propanediol MonohydratePolycystic ovary syndromeDapagliflozin Propanediol Monohydrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Dapagliflozin Propanediol/Metformin Hydrochloride | Tier A — Act now | 2030 |
| Ertugliflozin | Tier C — Watch / trade | - |
| Dapagliflozin Propanediol Monohydrate | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate→5-bromo-2-chlorobenzoic acid→ethoxybenzene→(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone→4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one
5-bromo-2-chlorobenzoic acid→ethoxybenzene→(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone→4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→L-proline compound with (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2:1)
(3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol→((2R,3R,4S,5R)-6-(allyloxy)-3,4,5-tris(benzyloxy)tetrahydro-2H-pyran-2-yl)methanol→((3S,4S,5R)-6-(allyloxy)-3,4,5-tris(benzyloxy)tetrahydro-2H-pyran-2,2-diyl)dimethanol→1-(bromomethyl)-4-methoxybenzene→(3S,4S,5R)-6-(allyloxy)-3,4,5-tris(benzyloxy)-2,2-bis(((4-methoxybenzyl)oxy)methyl)tetrahydro-2H-pyran→(3R,4S,5S)-3,4,5-tris(benzyloxy)-6,6-bis(((4-methoxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-ol→(3R,4S,5S)-3,4,5-tris(benzyloxy)-6,6-bis(((4-methoxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-one→N,O-dimethylhydroxylamine hydrochloride→(2R,3S,4S)-2,3,4-tris(benzyloxy)-5-hydroxy-N-methoxy-6-((4-methoxybenzyl)oxy)-5-(((4-methoxybenzyl)oxy)methyl)-N-methylhexanamide→4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene→(4S,5S)-3,4,5-tris(benzyloxy)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6,6-bis(((4-methoxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-ol→((2S,3S)-2,3,4-tris(benzyloxy)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6,8-dioxabicyclo[3.2.1]octan-1-yl)methanol
4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→(2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→((2R,3R,4S,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxy-3,4,5-tris((trimethylsilyl)oxy)tetrahydro-2H-pyran-2-yl)methanol→(2S,3R,4S,5R,6S)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxy-3,4,5-tris((trimethylsilyl)oxy)tetrahydro-2H-pyran-2-carbaldehyde→(2S,3R,4S,5S)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6,6-bis(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→(S)-5-oxopyrrolidine-2-carboxylic acid
(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate→5-bromo-2-chlorobenzoic acid→ethoxybenzene→(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone→4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one
5-bromo-2-chlorobenzoic acid→ethoxybenzene→(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone→4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene→(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one→(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol→L-proline compound with (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2:1)
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 4-(5-Bromo-2-chlorobenzyl)phenyl ethyl ether Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.